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Abstract: Daily intraperitoneal injection of cyclophosphamide (CPA) (50 mg·kg
-1 of body weight) for 5 days resulted in 
reduced levels of marrow and blood cellularity, which was most pronounced in 18 days post-treatment (pt). On day 18 af-
ter CPA treatment the enhanced
 levels of nitric oxide (NO) precursors and metabolites (L-arginine, L-citrulline, reactive 
nitrogen species (RNS)) of marrow and blood cells (platelet, neutrophil, lymphocyte and monocyte) resulted from up-
regulation of Ca(II)/calmodulin(CaM)-independent “inducible” NO synthase (iNOS), with a lesser
  contribution of 
Ca(II)/CaM-dependent “constitutive” cNOS isoforms to systemic NO. Biphasic response to CPA of marrow nitrergic sys-
tem, i.e. both iNOS and cNOS showed significantly depressed activities, as well as diminished levels of NO metabolites 
on day 9 pt, suggested that signals in addition to NO might be involved in CPA-induced inhibition of hematopoesis, while 
a gradual increase of neutrophil and platelet NOS activity appeared to be contributed to a CPA-induced development of 
granulopenia, thrombocytopenia and hemorrhage.  
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INTRODUCTION  
  Accumulating data suggest that an immunosuppressive 
drug cyclophosphamide (CPA) widely used in chemotherapy
 
mediates immunosuppressive and tumoricidal effects via 
nitric oxide (NO) and its reactive intermediates [reviewed in 
Ref. 1, 2]. NO controls expression of a wide range of anti-
proliferative genes through diverse signaling pathways [3, 
4]. Inhibition of the activation of nuclear transcription factor-
B (NF-B) in antigen-presenting cells is one of the molecu-
lar mechanisms of immunosuppressive drugs. Morphine me-
diates NO release in naloxone antagonized manner in mono-
cytes and neutrophils and thereby affects NF-B nuclear 
binding in these cells and a subsequent expression of pro-
inflammatory cytokines or adhesion molecules  [5].  NO is 
generated from L-arginine by a family NOS enzymes: the 
most known Ca(II)/ calmodulin (CaM) -dependent “constitu-
tive” NOS isoforms (cNOS), neuronal NOS (nNOS) and 
endothelial NOS (eNOS), that require CaM for activation 
and depend on the level of intracellular calcium to sustain 
bonding of CaM to their oxygenase domains, and 
Ca(II)/CaM-independent “inducible” NOS (iNOS), an effec-
tor molecule of the innate immune system, a regulatory 
component of host defense against pathogens and inflamma-
tion [reviewed in Ref. 6, 7]. Distinct NOSs have unique roles 
in mediating physiological responses or in responding to 
disease, and now should
 also be considered in the design of 
NO-related therapeutic targets  [reviewed in Ref. 8, 9]. 
cNOS-derived NO stabilizes the IB--NF-B inhibitory 
complex, reducing the release of pro-inflammatory media-
tors (the effectors of NF-B activation: TNF-, IL-1, IL-2, - 
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6, -8) – a process that is counteracted by iNOS-NO [10]. 
Therapy with CPA, which has a direct myelo-suppressive 
effect, has been related to a risk of developing cytopenia, 
leucopenia etc., associated with immune systems damage 
including nitrergic function. In this context, this study was 
performed to ascertain the CPA effect on the pharmacologi-
cally and functionally distinguished NOS isoforms. Here we 
report our initial observations on the NO generating system 
of blood and bone marrow in rat model of CPA-induced in-
hibition of hematopoiesis accompanied with granulopenia, 
thrombocytopenia and aplasia, as well. 
MATERIALS AND METHODOLOGY 
 N
G-monomethyl-L-arginine (NMMA) was obtained from 
Calbiochem (La Jolla, CA). All other reagents were pur-
chased from Sigma Chemical Co (St Louis, MO).  
Animal Care and Immunosuppression Procedure 
  All procedures involving animals were approved by the 
respective
 Institutional Animal Care and Ethics Committee 
of the National Academy of Sciences of the Republic of Ar-
menia. For
  all experiments, groups (n = 6/group) of adult 
female rats weighing 200–250 g were used. Animals were 
housed at a constant
 temperature and humidity, and
 had unre-
stricted access to a standard diet and tap water. Cyclophos-
phamide (50 mg·kg
-1 of body weight) reconstituted in sterile 
distilled water was administered via  intraperitoneal (i.p.) 
injection (500 μl) for 5 days. To confirm the duration of cy-
topenia, differential counts of blood and marrow samples 
were carried out, which showed that most of the tested rats 
remained cytopenic for up to 18 days post-treatment (pt). 
Animals were divided into groups: one group served as con-
trol and the other two as CPA-treated groups, in which rats 
were sacrificed by decapitation 9 days and 18 days after the 
last CPA administration.  82    The Open Biochemistry Journal, 2008, Volume 2  Kevorkian et al. 
Isolation of Blood Formed Elements and Marrow 
  Blood samples obtained at time of death were dissolved 
in 4 mM disodium-EDTA in a 9:1 ratio, mixed with 6% dex-
tran in a 2:1 ratio and incubated at 37
oC for an hour. After 
gravity sedimentation of erythrocytes the plasma layer con-
taining the remaining blood cells was centrifuged at 450 x g 
for 7 min and platelet-enriched plasma was separated from 
leucocyte-containing pellet. Platelets were separated from 
plasma by centrifugation at 900 x g for 20 min. Leucocytes 
were re-suspended in 20 mM HEPES buffer pH 7.4, in a 1:1 
ratio, layered over Ficoll/Hypaque double gradient media, 
density, 1.087/1.129 g/ml, and centrifuged at 600 x g for 30 
min [11]. Blood mononuclear cells from the upper layer and 
neutrophils from the bottom layer were collected. Mononu-
clears were incubated in plastic culture dishes for an hour at 
37
oC with 5% CO2  in air, and non-adherent lymphocytes 
were separated from adherent to the culture plate monocytes. 
Adherent monocytes were recuperated by gentle scraping 
with a plastic cell scraper after 15 min incubation with 2.5% 
disodium-EDTA at 37
oC.  
  Bone marrow was flushed from the cavity of long bones 
(the right and left hind limbs) homogenized in an ice-cold 20 
mM HEPES buffer, pH 7.4, filtered through a 70 μm filter to 
remove bone fragments and a mixture of marrow cells ob-
tained was used in experiments. 
  Cell preparations from blood and marrow before use 
were washed twice and re-suspended in 20 mM HEPES 
buffer, pH 7.4 For the measurement of cellular RNS, L-
arginine and L-citrulline content cells were washed twice 
with PBS, lysed with Triton-X-100, deproteinated with 0.5 N 
NaOH and 10% ZnSO4 or 12.5% TCA. Following a  cen-
trifugation at 900 x g for 5 min the supernatants were sam-
pled for analysis. Differential cell counts were performed 
using
 smear technique. Preparations used consisted of about 
90 to 95% viable cells as determined with the trypan blue 
dye exclusion assay.  
NOS Isoforms Assays  
  The NOS activity was assessed by an accumulation of 
reactive nitrogen species (RNS), i.e. NO and its stable 
intermediates (nitrogen oxides, ntrosothiols, etc.) produced 
by the cells during long-term incubation (at 37
oC for 22 h) in 
the incubation medium: 20 mM HEPES buffer pH 7.4, 
containing 2 mM DTT and 3 mM MgCl2·6H2O, (1.3 ml final 
volume). When incubated in the presence of 1.73 mM CaCl2, 
a total NOS activity of the cells was measured, whilst that 
iNOS - in the presence of 1.15 mM EDTA (omitting CaCl2 
from medium); cNOS activity was calculated by subtracting 
the iNOS activity from the total one. Parallel experiments 
were conducted, in which samples were incubated in the 
presence of 5.5 mM L-arginine, and NOS cofactors: 0.2 mM 
NADPH, 50 μM ((6R)-5,6,7,8-tetrahydro-L-biopterin dihy-
drochloride) (BH4), 5 μM FAD, 5 μM FMN. Reaction was 
initiated by addition of samples to the incubation medium 
and terminated by deproteination with 0.5 N NaOH and 10% 
ZnSO4 (as described above). The NOS activity expressed as 
nmol nitrite (NO2
-) · mg
-1 protein · 22 h
-1. 
Reactive Nitrogen Species Measurement 
  Samples deproteinated with 0.5 N NaOH and 10% 
ZnSO4 were analyzed for the RNS using colorimetric tech-
nique based on diazotization reaction detected NO and its 
derivatives, ntrosothiols, N-nitrosamines, nitrogen oxides 
(N2O4, N2O3, NO2
, NO3
) which are presented in the NO 
solutions even under the best (anaerobic) conditions [12]. 
Samples were mixed in equal parts with Griess-Ilosvay rea-
gent (1:1 mixture of 0.17% sulfanilic acid and 0.05% -
naphthylamine in 12.5% acetic acid), and 10 min later the 
diazo-coupled product was analyzed spectrophotometrically 
at 546 nm. All spectrophotometric absorbance readings for 
RNS were presented as nitrite and based on measuring with 
the Griess-Ilosvay reaction dilutions of the stock solution of 
NaNO2.  
L-Arginine and L-Citrulline Measurements  
  Samples deproteinated with 0.5 N NaOH and 10% 
ZnSO4 were analyzed for L-arginine according to [13] with 
our modification. Briefly: supernatants were added to a mix-
ture of equal amounts of 0.4 % 8-oxychinoline, 5 % sulpho-
salicilic acid, 0.01 M glycine buffer and 2.5% NaOH, stirred 
with 1 % sodium hypobromide (10:1) and 10 min later ana-
lyzed spectrophotometrically at 525 nm. Samples deprotein-
ated with 12.5 % TCA were analyzed for L-citrulline using 
test-system Bio La-Chema (Chechia). The concentrations of 
L-arginine and L-citrulline were calculated using their meas-
ured standards. 
  Protein concentration was measured according to [14] 
using crystalline bovine serum albumin as standard.  
Statistical Analysis 
  Data were expressed as the means ± S.E.M. and com-
pared using Student’s t-test. Relationships between bio-
chemical parameters were determined calculating the Pear-
son linear correlation coefficient (r). Differences were con-
sidered significant at P <
 0.05. 
RESULTS 
  To determine whether endogenous NO synthesis in vitro 
were detectable, long-term incubation of marrow and blood 
platelet and leucocyte subpopulations was established. NO 
and its reactive intermediates production by the cells was 
determined either in the absence or presence of the exoge-
nous substrate and cofactors of NOS in the incubation me-
dium. N
G-monomethyl-L-arginine (L-NMMA), which acts 
as a competitive inhibitor of both constitutive
 and inducible 
isoforms of NOS, at concentration of 2.5 mM, blocked in 
vitro NO generation, suggesting that NO was produced via 
L-arginine NO pathway (data not shown).  
NO Precursors and Metabolites in Blood and Marrow 
Following Cyclophosphamide Treatment 
  Daily intraperitoneal injection of CPA for 5 days (at the 
doses described in Materials and Methodology) resulted in 
reduced levels of marrow as well as circulating blood formed 
elements for up to 18 day pt (Figs. 1, 2).  
  However, on day 27 most of the animals showed some 
immune recovery from cytopenia. The cytopenic state of 
CPA-treated rats might be mimic the clinical situation in 
immunosuppressive therapy and was accompanied with the 
changes in the basal cellular levels of NO precursors and 
metabolites (L-arginine, RNS and citrulline) analyzed as a 
complementary test of in vivo nitrergic response to CPA Nitrergic Response TO Cyclophosphamide Treatment in Blood  The Open Biochemistry Journal, 2008, Volume 2    83 
treatment, and depended on pt time. Cellular L-arginine, 
RNS and L-citrulline contents of platelet, neutrophil and 
monocyte were gradually increased in 18 days pt (with ex-
ception for monocyte, in which arginine content was slightly 
decreased 9 day pt), while those of lymphocyte and marrow 
reduced 9 day pt and elevated 18 day pt (Figs. 3-5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Reduced numbers of marrow cell populations in cyclo-
phosphamide-treated rats. Groups of six age- and sex-matched rats 
(female) were treated with cyclophosphamide (50 mg/kg i.p.) for 5 
days. Animals were sacrificed 9 days and/or 18 days after final 
treatment, marrow samples underwent differential cell counts as 
described in Materials and Methodology. The data express a rela-
tive (%) number of cells (calculated from the control number of 
each cell population (100%) and that 9 day pt and/or 18 day pt) and 
are means ± S.E.M. P<0.05 compared with control. Note, the 
CPA’s inhibitory effect on marrow was more pronounced in 18 
days pt.  
  Levels of RNS and L-citrulline of marrow, neutrophil, 
lymphocyte and platelet were highly correlated (r= 0.9864; 
0.9876; 0.9978 and 0.9661, respectively, P<0.001), to a 
lesser extent a correlation between those of monocyte was 
observed (r= 0.3197, P<0.001), indicating that NOS reaction 
metabolites were involved in the other pathways in the latter 
cells.  
Nitrergic Response to Cyclophosphamide Treatment in 
Blood and Marrow 
  NO production by marrow and blood cells from control 
and CPA-treated rats are shown in Figs. (6-10). When incu-
bated in the presence of EDTA, all the cells from control rats 
exhibited the iNOS activity. In the calcium-containing me-
dium, the cells exerted the cNOS activity, with exception for 
neutrophil and lymphocyte, in which the cNOS was dis-
played only in the presence of arginine and NOS coactors. 
The mRNA of iNOS as well as eNOS and nNOS can be re-
liably detected in the mouse bone marrow [15]. The exis- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Reduced numbers of circulating blood formed elements in 
cyclophosphamide-treated rats. Groups of six age- and sex-matched 
rats (female) were treated with cyclophosphamide (50 mg/kg i.p.) 
for 5 days. Animals were sacrificed 9 days and/or 18 days after 
final treatment, and blood samples underwent hematologic analy-
sis.as described in Materials and Methodology. The data express a 
relative (%) number of cells (calculated from the control number of 
each cell population (100%) and that 9 day pt and/or 18 day pt) and 
are means ± S.E.M. P<0.05 compared with control. Note, the 
CPA’s inhibitory effect on blood differential count was more pro-
nounced in 18 days pt. 
 
tence of iNOS mRNA and protein has also been reported for 
rat neutrophil, eosinophil, megakaryocyte, and unstimulated 
monocyte, and those of eNOS of lymphocyte, megakaryo-
cyte, and platelet and nNOS of neutrophil [16-18]. It is not 
excluded that these isoforms contributed to the activity of 
cNOS and iNOS presented in rat marrow and blood, but 
strong NOS isoenzymes expression should be further deter-
mined at the level of transcription, translation and of enzyme 
activity to assess NOS isoenzymic spectra of the cells exam-
ined. However, under physiological circumstances constitu-
tively active cNOS and iNOS were presented in marrow, as 
well as blood immune cells, and platelet.  
  Our results show that marrow and blood cells could pro-
duce RNS during long-term incubation even in the absence 
of L-arginine and NOS cofactors, that on one hand suggest 
the availability of endogenous arginine for the cells, on the 
other, that citrulline, co-produced with NO could be con-
verted to arginine via the citrulline-NO cycle, which is gov-
erned by argininosuccinate synthase and argininosuccinate 
lyase expressed to some degree in nearly all cell types [re-
viewed in Ref. 19]. Nevertheless, the requirement for exoge-
nous L-arginine, NAD(P)H, BH4, thiols and flavin cofactors 
for a complete NOS assay system has been demonstrated, 
and L-arginine, as well as BH4 can promote and/or stabilize 
the active dimeric form of all three NOS isoforms [reviewed 
in Ref. 6]. All three NOS isoforms can make superoxide via 84    The Open Biochemistry Journal, 2008, Volume 2  Kevorkian et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Time-dependent effects of CPA on the cellular L-arginine 
level of marrow and blood platelet and leucocyte subpopulations. 
L-arginine was quantified immediately after isolation of the cells in 
samples deproteinated with 0.5 N NaOH and 10% ZnSO4. L-
arginine levels of platelet and neutrophil were gradually increased 
for up to 18 day pt, whereas that of monocyte was slightly de-
creased 9 day pt and markedly elevated 9 and 18 days pt. Contrary, 
L-arginine content of lymphocyte and marrow depleted 9 day pt 
and enhanced 18 day pt, but were lower than basal ones. Values are 
means ± S.E.M. P<0.05 compared with control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Time-dependent effects of CPA on the cellular L-citrulline 
level of marrow and blood platelet and leucocyte subpopulations. 
L-citrulline was quantified immediately after isolation of the cells 
in samples deproteinated with 12.5 % TCA. L- citrulline levels of 
platelet, neutrophil and monocyte were gradually increased 9 and 
18 days pt, while those of lymphocyte and marrow reduced 9 day pt 
and elevated 18 day pt. Values are means ± S.E.M. P<0.05 com-
pared with control. Note, citrulline can also serve as NO precursor 
through the citrulline-NO cycle. 
 
NADPH oxidation at sub-saturated concentration L-arginine 
and/or BH4 [reviewed in Ref. 20, 21]. Notably, a deleterious 
effect of excessive NO in the tissues is mediated by a potent 
oxidant, peroxynitite (ONOO
-, PN), that is readily formed 
whenever superoxide and NO are produced together [22]. 
Thus, parallel experiments were performed, where L-
arginine and NOS cofactors were included in the incubation 
mixture to determine in vitro a precise total NOS activity and 
prevent the possible superoxide formation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Time-dependent effects of CPA on the cellular NO and its 
reactive intermediates (RNS) level of marrow and blood platelet 
and leucocyte subpopulations. RNS were quantified immediately 
after isolation of the cells in samples deproteinated with 0.5 N 
NaOH and 10% ZnSO4. The RNS levels of platelet, neutrophil were 
gradually increased 9 and 18 days pt, while those of lymphocyte 
and marrow reduced 9 day pt and elevated 18 day pt. Monocyte 
showed remarkable increase of their RNS content 9 day pt, which 
decreased in 18 days pt, remaining higher than basal ones. Values 
are means ± S.E.M. P<0.05 compared with control.  
 
  Exogenous L-arginine and NOS cofactors increased the 
iNOS activity of about 1.7 times and that of cNOS only of 
1.07 times (compare: in the absence of L-arginine and NOS 
cofactors the cNOS activity of platelet was of 9 times higher  
than that iNOS). When incubated in the presence of L-
arginine and NOS cofactors lymphocyte and neutrophil ex-
hibited the cNOS activity, which in neutrophil was of 3.6 
times higher, than that of iNOS, while the cNOS activity of 
lymphocyte was about of 2.5 times lower than that of iNOS. 
These differences might be related to the differences in the 
NOS isoenzymic spectra of the cells, because cNOS of lym-
phocyte might be attributed to eNOS (vide supra), while 
cNOS of neutrophil to nNOS, which mRNA and protein 
have been shown in freshly isolated rat circulating neutro-
phils spontaneously producing RNS [23]. The NOS activity 
was equally distributed between iNOS and cNOS in mono-
cyte, which in the presence of L-arginine and NOS cofactors 
exerted an elevated activity of iNOS, which prevailed upon 
the activity of total NOS (determined in the presence of cal-
cium), therefore negative values of cNOS were calculated. It 
could be speculated that when EDTA was omitted from an 
incubation medium, exogenous arginine likely stimulate the 
activity of manganese-dependent arginase there through lim-
iting an availability of arginine for NO synthesis likewise it 
has been demonstrated in macrophage cultures [24]. How-
ever, the RNS production by marrow was diminished in the Nitrergic Response TO Cyclophosphamide Treatment in Blood  The Open Biochemistry Journal, 2008, Volume 2    85 
presence of exogenous L-arginine and NOS cofactors regard-
less of presence either EDTA or calcium in the incubation 
medium, indicating that other metabolic processes possibly 
interfered with the NOS reaction in the cells.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Time-dependent effects of CPA on the activity of distinct 
NOS isoforms of marrow. Activity measurements were performed 
as described in Materials and Methodology and assessed by RNS 
accumulation in vitro after long-term incubation of marrow isolated 
from control rats (1) and CPA-treated rats sacrificed 9 days (2) and 
18 days (3) after final treatment. Exogenous arginine and NOS 
cofactors reinforced the cNOS inhibition in marrow of CPA-treated 
rats. Values are means ± S.E.M. P<0.05 compared with control. 
Note, negative values of RNS were calculated, when the RNS lev-
els determined  before incubation were higher than the one after 
long-term incubation of the cells, and indicated to a prevalence of 
NO breakdown processes upon its synthesis (this is also concerned 
to Figs. (7-10). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Time-dependent effects of CPA on the activity of distinct 
NOS isoforms of platelet. Activity measurements were performed 
as described in Materials and Methodology and assessed by RNS 
accumulation in vitro after long-term incubation of platelet isolated 
from blood of control rats (1) and CPA-treated rats sacrificed 9 
days (2) and 18 days (3) after final treatment. Stimulatory effect of 
exogenous arginine and NOS cofactors on both iNOS and cNOS of 
platelet observed for conrol rats was restored in CPA-treated rats in 
18 days pt. Values are means ± S.E.M. P<0.05 compared with con-
trol.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (8). Time-dependent effects of CPA on the activity of distinct 
NOS isoforms of neutrophil. Activity measurements were per-
formed as described in Materials and Methodology and assessed by 
RNS accumulation in vitro after long-term incubation of neutrophil 
isolated from blood of control rats (1) and CPA-treated rats sacri-
ficed 9 days (2) and 18 days (3) after final treatment. Both iNOS 
and cNOS of neutrophil were stimulated with exogenous arginine 
and NOS cofactors in neutrophil of contrl rats, and inhibited com-
pletely in CPA-treated rats in 18 days pt. Values are means ± 
S.E.M. P<0.05 compared with control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (9). Time-dependent effects of CPA on the activity of distinct 
NOS isoforms of lymphocyte. Activity measurements were per-
formed as described in Materials and Methodology and assessed by 
RNS accumulation in vitro after long-term incubation of lympho-
cyte isolated from blood of control rats (1) and CPA-treated rats 
sacrificed 9 days (2) and 18 days (3) after final treatment. Stimula-
tory effect of exogenous arginine and NOS cofactors on both iNOS 
and cNOS of lymphocyte was observed for conrol rats and restored 
and intensified in CPA-treated rats in 18 days pt Values are means 
± S.E.M. P<0.05 compared with control.  86    The Open Biochemistry Journal, 2008, Volume 2  Kevorkian et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (10). Time-dependent effects of CPA on the activity of distinct 
NOS isoforms of monocyte. Activity measurements were per-
formed as described in Materials and Methodology and assessed by 
RNS accumulation in vitro after long-term incubation of monocyte 
isolated from blood of control rats (1) and CPA-treated rats sacri-
ficed 9 days (2) and 18 days (3) after final treatment. The effect of 
exogenous arginine and NOS cofactors on the NOS isoforms activ-
ity of control monocyte (i.e. stimulation of the iNOS and inhibition 
of the cNOS) was restored in those ones in 18 days pt. Values are 
means ± S.E.M. P<0.05 compared with control.  
 
  On day 9 after CPA treatment the activities of both cNOS 
and iNOS were depleted in marrow and blood lymphocyte 
and accompanied with the impaired levels of arginine, RNS 
and citrulline of the cells, compared to control. Added L-
arginine and NOS cofactors influenced negatively the RNS 
production by marrow, and intensified a drop in the RNS 
content of lymphocyte incubated in the presence of calcium, 
but increased it in the presence of EDTA. At the same time, 
the cNOS activity was manifested in neutrophil (the iNOS 
was decreased 1, 26 times) and contributed to a remarkable 
increase in a total NOS activity accompanied with elevated 
levels of arginine, RNS and citrulline of the cells. Both plate-
let and monocyte also exhibited enhanced levels of RNS and 
citrulline, although in vitro their RNS production was 
dropped 9 day pt, compared to control. These discrepancies 
between  in vivo and in vitro testing of nitrergic activity 
should be further investigated, and may be caused by differ-
ences in microenvironment. Added L-arginine and NOS co-
factors reinforced a drop in the RNS production by mono-
cyte in the presence either calcium or EDTA 9 day pt. Of 
interest, on 9 day pt L-arginine and NOS cofactors in the 
presence of calcium intensified a decrease in the RNS pro-
duction by all the cells examined, whereas in the presence of 
EDTA they attenuated it in platelet and markedly increased 
the iNOS activity of neutrophil and lymphocyte, once more 
suggesting a regulatory role of bivalent cations, including 
calcium, in the effects observed. Our data also suggest that 
L-arginine and NOS cofactors could alter in vivo nitrergic 
response of marrow and blood to CPA because of competi-
tion between NOSs and arginine-metabolizing enzymes 
and/or NADPH oxidase, possibly stimulated following CPA 
treatment (vide infra).  
  On day 18 after CPA treatment an elevated immunosup-
pression was accompanied with a significant enhancement of 
arginine, RNS and citrulline content of all the cells studied 
associated with up-regulation of both iNOS and cNOS of 
blood cells and the iNOS of marrow , compared to control 
(neutrophil cNOS activity was reduced, but remained mark-
edly higher, than control one). Conversely, the cNOS of mar-
row was completely suppressed. Of note, the iNOS was in-
creased drastically in platelet, whereas all leucocyte exerted 
the most pronounced increase in the cNOS activity. Though, 
the iNOS dominated in these cells with exception for mono-
cyte, in which the cNOS activity was 2.6 times higher, than 
that of iNOS. Notably, a stimulatory effect of L-arginine and 
NOS cofactors on the NOS isoforms of platelet and lympho-
cyte seen in control rats was restored in those of CPA-treated 
animals 18 day pt. At the same time, L-arginine and NOS 
cofactors depleted the activity of both cNOS and iNOS of 
neutrophil and that cNOS of monocyte, as well as caused a 
great decrease in the RNS level of marrow during long-term 
incubation in the presence of calcium. Contrary, the iNOS of 
marrow reduced slightly by L-arginine and NOS cofactors, 
while it was inhibited in control cells.  
DISCUSSION 
  Our pilot study demonstrates that under physiological 
circumstances both cNOS and iNOS isoforms
  were repre-
sented in a unique distribution in marrow and blood platelet 
and leucocyte subpopulations of adult female rat, once more 
implying a homeostatic role for iNOS. Our data are in 
agreement with findings that the mentioned NOS isoforms 
constitutively operate in the immune system [15-18].  It 
should be noted that endogenous NO synthesis in vitro as-
sessed by accumulation of RNS during long-term incubation 
of cells reflects such counteracted processes, as NO synthe-
sis and its breakdown, and in case of a prevalence of the NO 
breakdown processes upon its synthesis negative values for 
the NOS activity are calculated, as for the cNOS (as de-
scribrd in Materials and Methodology) of control neutrophil 
and lymphocyte, which RNS production in the presence of 
calcium was lower, than that in the presence of EDTA. Thus, 
the NO breakdown processes of these cells are up-regulated 
(under EDTA omitting conditions) by bivalent cations, par-
ticularly calcium. Calcium could trigger a priming of 
NADPH oxidase in immune cells and enhance superoxide 
concentration [25, 26] with subsequent formation of PN and 
impairment of NO. Notably, granulocyte, monocyte and 
lymphocyte challenged by lipopolysaccharide can produce 
PN and deplete NO during long-term incubation [27]. Acti-
vated human neutrophils cause rapid breakdown of added 
exogenous NO also due to formation of PN [28]. These 
processes  appear to be activated following CPA treatment 
(vide infra).  
  In parallel experiments L-arginine and NOS cofactors 
combined to either EDTA or calcium in the incubation me-
dium increase the activities of both cNOS and iNOS in blood 
cells (except monocyte cNOS, which is inhibited). Contrary, 
L-arginine and NOS cofactors cause a remarkable drop of 
the RNS level of marrow incubated in the presence of either 
calcium or EDTA (up to negative values). It could be specu-
lated that added L-arginine provokes a competition for argin-
ine between NOS and arginine-metabolizing enzymes, such 
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ADP-ribosyltransferase (ADPRTA) etc, [reviewed in Ref. 
19, 29] in the above mentioned cells. Of note, arginase can 
completely deplete circulating L-arginine thereby signifi-
cantly reducing the formation of NO [30]. Moreover, iNOS 
can be inhibited by urea produced in arginase reaction [31]. 
Pretreatment with arginase inhibitors directly restored NO 
signalling and arginine responsiveness in aged vessels, as 
well as in the age-associated decline in cutaneous vasodila-
tory function [32-34]. Thus, arginase may limit the available 
pool of L-arginine for NOS and therefore the bioavailability 
of NO. Although, the unique and relatively potent inhibition 
of arginase by the biosynthetic intermediate in NO genera-
tion, N
G-hydroxy-L-arginine suggests an alternate means of 
regulation in tissues and cells (such as macrophages), that 
contain both NOS and arginase [35]. Though ADC-derived 
agmatine is also a competititve inhibitor of the NOS iso-
forms in macrophages and irreversibly inhibits nNOS and 
down-regulate iNOS in brain [36, 37]. Thus, cellular NO 
synthesis rates are regulated via a variety of mechanisms that 
control the availability of arginine [reviewed in Ref. 39]. 
Undoubtedly, differences in the distribution and expression 
of the above mentioned enzymes should be contributed to 
the differences in nitrergic response of blood and marrow.  
  Hence, the physiological relevance of the in vitro testing 
systems needs to be carefully evaluated, as in the more 
physiologically relevant condition NO synthesis can exhibit 
features that do not precisely match the properties of NOS as 
in vitro assessed. A typical example is the `arginine paradox' 
for NO synthesis, which refers to the dependence of cellular 
NO production on exogenous L-arginine concentration de-
spite the theoretical saturation of NOS enzymes with intra-
cellular L-arginine [38]. Indeed, in our study in vitro tactiva-
tion and inhibition of distinct NOSs are highly depended on 
concentrations of calcium, L-arginine and NOS cofactors, 
and a chelator agent EDTA, as well. Moreover, the basal 
levels of NO precursors and metabolites V of the cells meas-
ured as a complementary test of in vivo nitrergic response are 
not always coincided with a total NOS activity determined in 
a test tube. Therefore, parallel experiments conducted with 
L-arginine and NOS cofactors in the NOS assay, as well as 
determination of basal levels of NOS metabolites of the cells 
are helpful for clearly understanding of in vivo occurred in-
tracellular processes.  
  The metabolic pattern studied is significantly changed in 
a CPA-immunosuppressed rat model. CPA-associated mye-
losuppression, hepatotoxicity and other adverse effects ef-
fects are generally known as a response to a reduction in 
dosage or withdrawal. In our study the capacity of CPA to 
either activate or suppress the nitrergic response of marrow 
and blood is changed in a time-dependent manner, possibly 
related to the retained CPA’s level in the body. Interestingly, 
immunosuppressive effects of CPA are more pronounced on 
18 day pt, than 9 day pt, indicating to an efficiency of low 
doses of CPA, which also up-regulate of NOS/NO system of 
marrow and blood. Of note, on 9 day after the last CPA ad-
ministration, the inhibition of hematopoesis is accompanied 
with diminished cellular levels of L-arginine, L-citrulline 
and RNS (4.2; 1.6 and 1.9 times, respectively), and an im-
pairment of the NO synthesis in marrow, associated with the 
inhibition of both iNOS and cNOS. The inhibition is rein-
forced by L-arginine and NOS cofactors, which can affect 
not only NOS isoforms, but also arginine-metabolizing en-
zymes, NADPH oxidase etc. Of note, the levels of L-
arginine and NO metabolites are significantly higher in both 
marrow and lymphocyte than in the rest of the cells from 
control rats, and unlike the latter cells they were decreased in 
both marrow and lymphocyte 9 day pt, indicating to utiliza-
tion of L-arginine via other pathways. Though, L-arginine 
and NOS cofactors increase the iNOS activity of lympho-
cyte, as well as that of neutrophil 9 day pt, suggesting the 
negative effects of bivalent cations on the NOSs with possi-
ble involvement of NADPH oxidase activated by calcium.  
  Since, a decrease of marrow nitrergic response is sug-
gested by in vitro and in vivo testing 9 day pt, at this stage 
CPA-induced inhibition of hematopoesis should be provided 
by other mechanisms. Recently an increased proliferation of 
neural stem cells has been demonstrated in newborn arginase 
isoenzyme 1 knockout mice, showing an unanticipated role 
of arginase in cell growth [39]. Thus, arginase on one hand 
could inhibit NOS isoforms, on the other prevent cell prolif-
eration. Besides, ADC-derived agmatine can also suppress 
cell proliferation through an inhibition of ornithine decar-
boxylase by inducing synthesis of antizyme, a protein that 
inhibits polyamine biosynthesis and transport [40]. Never-
theless, it should be further investigated whether CPA can 
activate arginine-metabolizing enzymes, interfering with the 
NOS reaction, as discussed above.  
 Enhanced
  level of marrow RNS resulted from the up-
regulation of iNOS increased 3.5, times, compared to con-
trol, while the cNOS completely suppressed. Contrary to 
marrow, a gradual increase of neutrophil levels of NOS reac-
tion metabolites are observed resulted from the up-regulation 
of both iNOS and cNOS that might be involved in the devel-
opment of granulopenia, and cytopenia in blood 9 and 18 
days pt. On 9 day after CPA treatment despite of an impair-
ment of the activity of both iNOS and cNOS of platelet and 
monocyte, the coincident elevation of their citrulline and 
RNS levels is observed (arginine level of platelet is also in-
creased, whilst that of monocyte is reduced slightly), possi-
bly indicating to an elevation of the NO synthesis. At the 
same time, L-arginine and NOS cofactors combined to cal-
cium decrease in vitro the RNS production by all the cells 
studied, while combined to EDTA they stimulate the iNOS, 
with exception for monocyte and marrow. One of the possi-
ble explanations of this phenomenon is that on day 9 pt CPA 
induced activation of NADPH oxidase, which in the pres-
ence of calcium elevated superoxide production and in-
creased cellular NO breakdown rates in these cells with a 
subsequent formation PN, which is involved in
  the patho-
genesis of conditions associated with CPA treatment [41, 
42]. CPA has been reported enhances the generation of su-
peroxide
 by NADPH oxidase [43]. Notably, arginase could 
also increase superoxide production by myeloid cells 
through a pathway that likely uses the reductase domain of 
iNOS [44]. In CPA-administered rats the antioxidant en-
zymes (superoxide dismutase, catalase, glutathione peroxi-
dase, glutathione-S-transferase, glutathione reductase and 
glucose-6-phosphate dehydrogenase) showed significantly 
depressed activities, as well as diminished levels of reduced 
glutathione, ascorbate and a-tocopherol [45]. In turn, super-
oxide and H2O2 contribute to inflammation by induction of 
intracellular calcium [46]. CPA is shown to affect the ability 
of heart or liver mitochondria to retain accumulated calcium 
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  It should be noted, that direct toxicity of NO per se is 
modest, but greatly increased on reaction with superoxide to 
form PN [22, 48]. PN is responsible for the T cell-dependent 
oxidative/nitrative stress facilitated by CPA after bone mar-
row transplantation [42]. PN anion reacts with biological 
targets, including CO2, in the presence of which nitration 
yields are increased by 2 to 4-fold [49]. Protonation of PN 
(pKa of 6.8 at 37
oC) results in formation of peroxynitrous 
acid wich is unstable and undergoes either decomposition to 
nitrate and O2 (at pH values  7.0) or isomerization (pre-
dominant at low pH (<7.0)) to nitrate, which thereafter could 
be reduced to nitrite and NO [50, 51]. These long lasing 
processes are contributed to the elevated basal RNS level 
observed, whereas in vitro testing shows a drop of the RNS 
production by platelet and monocyte. Notably, L-arginine 
and NOS cofactors combined to EDTA increase the iNOS 
activity of neutrophil and lymphocyte, and attenuate an im-
pairment of the cellular RNS content of platelet during long-
term incubation. Thus, PN formation by blood cells could be 
occurred due to activation of cellular NADPH  oxidase in 
CPA-treated rats 9 day pt. Nevertheless, when incubated 
with EDTA, monocyte exhibit the most remarkable decrease 
in the RNS level, which reinforced greatly by L-arginine and 
NOS cofactors, indicating to the involvement of arginine-
metabolizing enzymes, as well as other interfering metabolic 
processes linked to NOS cofactors. L-arginine and NOS co-
factors combined to calcium markedly reduce the RNS level 
of monocyte, neutrophil and marrow during long-term incu-
bation even on day 18 pt, that also suggest an opportunity of 
that kind of scenery.  
  It is not excluded that CPA-induced elevation of intracel-
lular calcium concentrations trigger an up-regulation of 
cNOS observed in all leucocyte subpopulations 18 day pt, 
(the cNOS even dominates in monocyte - its activity is 2.6 
times higher than that iNOS). However, both iNOS and 
cNOS are up-regulated by CPA in blood immune cells. Both 
iNOS and cNOS (nNOS and eNOS) are involved in the 
compatible regulation of leucocyte recruitment, and iNOS-
derived NO inhibits platelet aggregation and platelet and 
leucocytes adhesion in the microvasculature, modulates cy-
toskeletal function [reviewed in Ref. 52]. It is of importance, 
that NO could facilitate down-regulation of intracellular 
Ca
2+concentration via an activation of either soluble guany-
late cyclase in vivo and increasing cGMP level [53] or 
ADPRT A (found in polymorphonuclear leucocyte, lympho-
cyte and monocyte [54-56]) stimulating mono-ADP-
ribosylation of actin in association with inhibition of actin 
polymerization [53, 57]. Besides, NO in macrophages led to 
post-transcriptional inhibition of xanthine dehydro-
genase/xanthine oxidase, possibly minimizing the potential 
for tissue injury from XO released from macrophages into 
the inflammatory milieu [58]. Formation of hydroxyl
 radicals 
(·OH) by the superoxide-driven fenton reaction can be pre-
vented by NO, which can also attenuate lipid peroxidation 
[59]. Ameliorating effects of iNOS-derived NO as an anti-
oxidant, antimicrobial and tumoricidal agent has been re-
ported [7, 60]. Thus, NOS/NO system could modulate dele-
terious side effects of CPA treatment via a variety of mecha-
nisms preventing oxidative stress and might be contributed 
to the attenuation of CPA’s effect on the pro-oxidant system 
[43]. Finally, NO itself may switch the mechanisms of feed-
back inhibition of both nNOS and iNOS through formation 
of inhibitory nitrosyl species [reviewed in Ref. 6]. Recently, 
a novel negative feedback mechanism has been revealed 
whereby NO down-regulates iNOS gene expression and NO 
production by inhibiting the post-translational processes of 
IkappaBalpha there through preventing NF-kappaB activa-
tion [61]. However, CPA-induced upregulation of NOS iso-
forms of platelet, especially iNOS (elevated 10.7 times com-
pared to control), could be contributed to overproduction of 
NO. Of note, iNOS can produce NO for prolonged periods 
[62]. NO may directly attenuate the activation of platelet, 
preventing the expression of P-selectin, secretion of platelet 
granules, intracellular calcium flux, as well as binding of 
glycoprotein IIb/IIIa to fibrinogen, but could also result in 
severe detrimental consequences [50], particularly in hemor-
rhage developed following CPA treatment. A rapid increase 
in hepatic NO during hemorrhagic shock has been reported 
[63].  
 Enhanced
  level of marrow RNS is observed associated 
with the up-regulation of iNOS increased 3.5, times, com-
pared to control, while the cNOS is completely suppressed 
18 days following CPA treatment. CPA-induced down-
regulation of cNOS (eNOS and nNOS) may influence the 
effects driven by these isoforms. nNOS has been shown acts 
as a paracrine effector to regulate hematopoiesis in bone 
marrow [64]. Recently a role of eNOS in mobilization of 
stem and progenitor cells has been demonstrated [65]. Nev-
ertheless, the iNOS-derived NO might be involved in the 
regulation of hematopoiesis as reported for murine granulo-
cyte-containing fraction of marrow, which largely produced 
NO, there through suppressing cellular proliferation [66]. 
NO can establish a dominant antiproliferative tone to help 
protect the stem cell pool from premature depletion when 
challenged with stressful stimuli [18, 67]. CPA induces the 
development of early myeloid cells with a potential antitu-
mor effect that may be
 strongly antiproliferative through NO 
production [2]. Of interest, at sub-saturating L-arginine, BH4 
concentrations, or in the presence of some NOS inhibitors, 
such as naturally occurring NMMA, iNOS may produce 
much lower amounts of superoxide than production by 
nNOS or eNOS [68-70]. We believe that low doses of CPA 
may be useful in strategies to increase NO availability and 
antioxidants combined to therapies against NADPH oxidase 
and other pro-oxidant systems to decrease reactive oxygen 
species generation there through minimizing deleterious 
processes associated with several pathological states [71].  
CONCLUSION 
  Taken together, our results indicate that functionally dis-
tinguished Ca(II)/CaM-dependent- and independent NOS 
isoforms are differentially in a time-dependent manner regu-
lated in blood and marrow in a CPA’s immunosuppressive 
model of rat. On 9 day after CPA treatment in vivo and in 
vitro testing suggest a down-regulation of both cNOS and 
iNOS in marrow indicating that signals in addition to NO 
appear to be involved in the inhibitory effect of CPA on he-
matopoiesis. The most pronounced inhibition of hematopoe-
sis, as well as granulopenia, thrombocytopenia, aplasia, and 
hemorrhage observed in 18 days pt are accompanied with the 
enhanced
  levels of the NOS substrate and metabolites (L-
arginine, RNS and L-citrulline) due to up-regulation of iNOS 
in marrow and blood formed elements (erythrocyte were not 
sudied). CPA increases thoroughly the cNOS activity of all Nitrergic Response TO Cyclophosphamide Treatment in Blood  The Open Biochemistry Journal, 2008, Volume 2    89 
the leucocyte subpopulations indicating to a possible contri-
bution of the constitutive
 isoforms of NOS to the develop-
ment of CPA’s immunosuppressive effects in blood, which 
may be also important in the design of therapeutic
 agents. 
Contrary, a complete inhibition of marrow cNOS was ob-
served 18 day pt that may influence the effects driven by 
nNOS and eNOS in hematopoesis. L-arginine and NOS co-
factors affect in vitro the activity of distinct NOS isoforms of 
marrow and blood platelet and leucocyte subpopulations 
from control and CPA treated rats suggesting the involve-
ment of L-arginine metabolic pathways, as well as pro-
oxidant system, including NADPH oxidase in the regulation 
of nitrergic response of marrow and blood. Thus, a CPA-
induced prolonged cytopenia is accompanied with a time-
dependent complex nitrergic response and suggests a com-
plex regulatory network involved in
 the pathogenesis of con-
ditions associated with CPA treatment and should be taking 
into account considering this in the design of chemoimmuno-
therapy
 sequencing.  
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